Filiz Çay Şenler

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares, Alexander Luft, David Vicente et al. · New England Journal of Medicine · 2018 · 3.6K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15

Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC).

Luis Paz‐Ares, Alexander Luft, Ali Tafreshi et al. · Journal of Clinical Oncology · 2018 · 121 citations

Medicine, Oncology, Pharmacology +16

Impact of TNF-α and IL-6 Levels on Development of Cachexia in Newly Diagnosed NSCLC Patients

Oya Kayacan, Demet Karnak, Sumru Beder et al. · American Journal of Clinical Oncology · 2006 · 79 citations

Medicine, Immunology, Oncology +10

Severe drug interactions and potentially inappropriate medication usage in elderly cancer patients

Ali Alkan, Arzu Yaşar, Ebru Karcı et al. · Supportive Care in Cancer · 2016 · 77 citations

Medicine, Oncology, Pharmacology +16